BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36096374)

  • 1. Treatment patterns and healthcare utilization of patients with treatment-resistant depression estimated using health insurance database: A population-based study from Taiwan.
    Huang WL; Chiang CL; Wu CS; Liao SC; Chien TH; Tseng CH; Tang CH
    J Affect Disord; 2022 Dec; 319():40-47. PubMed ID: 36096374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan.
    Fife D; Feng Y; Wang MY; Chang CJ; Liu CY; Juang HT; Furnback W; Singh J; Wang B
    Psychiatry Res; 2017 Jun; 252():277-283. PubMed ID: 28288438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
    Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
    JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of Treatment-Resistant Depression in the United States.
    Liu X; Mukai Y; Furtek CI; Bortnichak EA; Liaw KL; Zhong W
    J Clin Psychiatry; 2021 Nov; 83(1):. PubMed ID: 34851558
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost analysis of depression using the national insurance system in South Korea: a comparison of depression and treatment-resistant depression.
    Shin D; Kim NW; Kim MJ; Rhee SJ; Park CHK; Kim H; Yang BR; Kim MS; Choi GJ; Koh M; Ahn YM
    BMC Health Serv Res; 2020 Apr; 20(1):286. PubMed ID: 32252762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
    Olfson M; Amos TB; Benson C; McRae J; Marcus SC
    J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study.
    Mahlich J; Tsukazawa S; Wiegand F
    Drugs Real World Outcomes; 2018 Mar; 5(1):35-43. PubMed ID: 29185233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study.
    Lähteenvuo M; Taipale H; Tanskanen A; Rannanpää S; Tiihonen J
    J Affect Disord; 2022 Jul; 308():236-242. PubMed ID: 35398108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study.
    Brenner P; Brandt L; Li G; DiBernardo A; Bodén R; Reutfors J
    Addiction; 2020 Apr; 115(4):768-777. PubMed ID: 31656053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Database Studies of Treatment-Resistant Depression Should Take Account of Adequate Dosing.
    Fife D; Blacketer C; Reps JM; Ryan P
    Prim Care Companion CNS Disord; 2018 Jul; 20(4):. PubMed ID: 30084549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea.
    Kim N; Cho SJ; Kim H; Kim SH; Lee HJ; Park CHK; Rhee SJ; Kim D; Yang BR; Choi SH; Choi G; Koh M; Ahn YM
    PLoS One; 2019; 14(8):e0221552. PubMed ID: 31442296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment resistant depression in women with peripartum depression.
    Cepeda MS; Kern DM; Nicholson S
    BMC Pregnancy Childbirth; 2019 Sep; 19(1):323. PubMed ID: 31477032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
    Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D
    Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.
    Sharman Moser S; Chodick G; Gelerstein S; Barit Ben David N; Shalev V; Stein-Reisner O
    BMC Psychiatry; 2022 Aug; 22(1):541. PubMed ID: 35948895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records.
    Adekkanattu P; Olfson M; Susser LC; Patra B; Vekaria V; Coombes BJ; Lepow L; Fennessy B; Charney A; Ryu E; Miller KD; Pan L; Yangchen T; Talati A; Wickramaratne P; Weissman M; Mann J; Biernacka JM; Pathak J
    J Affect Disord; 2023 Mar; 324():102-113. PubMed ID: 36529406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care.
    Liberman JN; Davis T; Pesa J; Chow W; Verbanac J; Heverly-Fitt S; Ruetsch C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):987-995. PubMed ID: 32715964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.